

Index

- 5HT1A receptor partial agonists
vilazodone, 64–66
- 5HT2A receptor antagonists, 82
- 5HT2C receptor antagonists, 77–82
fluoxetine, 61
- 5HT3 receptor antagonists, 82–86
- acetaminophen, 104
- Adapin, 106
- agomelatine, 77–81
- Akiskal, Hagop, 7
- alpha 2 antagonists, 81–86
- amitifidine (triple reuptake inhibitor), 129
- amitriptyline, 106
- amoxapine, 106
- amphetamine, 91
- Anafranil, 106
- analgesics
interactions with MAOIs, 104
- anesthetics
interactions with MAOIs, 99
- antidepressant action,
comparison with placebo in clinical trials, 49
- debate over efficacy, 49–51
- definition of a treatment response, 49
- disease progression in major depression, 53
- effects throughout the life cycle, 53
- efficacy in clinical trials, 49–51
- failure to achieve remission, 51
- general principles, 49–53
- goal of sustained remission, 49
- importance of achieving remission, 53
- in “real world” trials, 53
- STAR-D trial of antidepressants, 51
- antidepressant augmenting agents, 110–117
- brain stimulation techniques, 114–116
- bupropion, 65–66
- deep brain stimulation (DBS), 115–116
- electroconvulsive therapy (ECT), 114
- L-methylfolate, 110–114
- psychotherapy as an epigenetic “drug”, 116–117
- SAMe (S-adenosyl-methionine), 114
- thyroid hormones, 114
- transcranial magnetic stimulation (TMS), 114–115
- antidepressant classes
- 5HT2C antagonism, 77–81
- alpha 2 antagonists, 81–86
- circadian rhythm resynchronizer, 77–81
- melatonergic action, 77–81
- monoamine oxidase inhibitors (MAOIs), 90–106
- monoamine transporter blockers, 53–110
- norepinephrine–dopamine reuptake inhibitors (NDRIs), 73–76
- selective norepinephrine reuptake inhibitors (NRIs), 76–77
- serotonin antagonist/reuptake inhibitors (SARIs), 86–90
- serotonin–norepinephrine reuptake inhibitors (SNRIs), 66–73
- serotonin partial agonist-reuptake inhibitors (SPARIs), 64–66
- serotonin selective reuptake inhibitors (SSRIs), 54–64
- tricyclic antidepressants, 76, 106–110
- antidepressant-induced mood disorders, 11–14
- antidepressant “poop-out”, 9
- antidepressant selection
- arousal combos, 129
- based on genetic testing, 125–126
- based on weight of the evidence, 125–126
- breastfeeding patient, 125
- California rocket fuel (SNRI plus mirtazapine), 127
- combination therapies for major depressive disorder, 126–129
- combination therapies for treatment-resistant depression, 126–129
- depression treatment strategy, 48–49
- equipose situation, 125–126
- evidence-based selection, 117–118
- postpartum patient, 125
- for pregnant patients, 121–125
- symptom-based approach, 118–121
- triple action combination (SSRI/SNRI/NDRI), 126–127
- for women based on life-cycle stage, 121
- for women of childbearing age, 121–125
- antidepressants in development
- CRF1 (corticotrophin-releasing factor) antagonists, 129
- future treatments for mood disorders, 129–130
- glucocorticoid antagonists, 129
- multimodal agents, 129–131
- NMDA blockade, 129–130
- serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRI), 129
- triple reuptake inhibitors (TRIs), 129
- vasopressin 1B antagonists, 129
- antihistamines, 99
- anxiety disorders, 32, 54, 91
- aripiprazole, 64
- Asendin, 106
- aspirin, 104
- atomoxetine, 76
- attention deficit hyperactivity disorder (ADHD), 74
- atypical antipsychotics, 9
- atypical depression, 9
- Aventyl, 106
- avoidant personality disorder, 9
- BDNF (brain-derived neurotrophic factor), 54
- effects of depression, 77
- stress effects, 32–33
- benzodiazepines, 99, 105
- BH4 (tetrahydrobiopterin), 110
- bipolar depression, 1–2
- distinguishing from unipolar depression, 14–16
- bipolar disorder
- comorbid with dementia, 14

- bipolar disorder NOS (not otherwise specified), 7–8
- bipolar I disorder, 2
- bipolar II disorder, 2
- bipolar spectrum, 7–14
- bipolar ¼ (0.25) disorder, 9
 - bipolar ½ (0.5) disorder, 7–11
 - bipolar I ½ (1.5) disorder, 12
 - bipolar II ½ (2.5) disorder, 11
 - bipolar III (3.0) disorder, 11–14
 - bipolar III ½ (3.5) disorder, 15
 - bipolar IV (4.0) disorder, 12–16
 - bipolar V (5.0) disorder, 12–14
 - bipolar VI (6.0) disorder, 14
- and schizoaffective disorder, 7–11
- schizo-bipolar disorder, 7–11
- BMS-820836 (triple reuptake inhibitor), 129
- brain atrophy and depression, 32–33
- brain stimulation
- as antidepressant augmentation, 114–116
- breastfeeding patient
- depression treatment, 125
- brief psychotic disorder, 9
- brompheniramine, 99
- bupropion, 62
- formulations, 75
 - pharmacologic properties, 73–76
- bupirone, 110
- augmentation of SSRIs, 65–66
- California rocket fuel (SNRI plus mirtazapine), 82, 127
- carbamazepine, 104
- catatonic depression, 9
- chlomipramine, 106
- chlorpheniramine, 99
- chlorpromazine, 107
- circadian rhythms
- disruption in depression, 77–81
- citalopram
- enantiomers, 63
 - racemic citalopram, 63–64
 - unique properties, 63
- See also* escitalopram
- clock genes, 77
- clomipramine, 103–104, 107–108
- Coaxil, 106
- cocaine, 62
- codeine, 99, 104
- cognitive behavioral therapy, 117
- COMT (catechol-O-methyltransferase), 21, 112
- genetic variants, 112–114
- continuum disease model, 9–11
- cortisol secretion
- elevation in depression, 77
- CRF1 (corticotrophin-releasing factor) antagonists, 129
- cyclobenzaprine, 104
- cyclothymic disorder, 2
- CYP450 (cytochrome P450) enzymes
- using genotypes to predict drug effects, 125
- CYP450 2D6 polymorphism
- effects on metabolism of venlafaxine, 71
- decongestants
- interactions with MAOIs, 99
- deep brain stimulation (DBS), 115–116
- delusional disorder, 9
- dementia
- with comorbid bipolarity, 14
- Deplin, 110
- depression, 1–2, 9
- benefits of early intervention, 53
 - brain atrophy and stress, 32–33
 - deep brain stimulation (DBS), 115–116
 - disease progression concept, 53
 - disruption of circadian rhythms, 77–81
 - distinguishing unipolar from bipolar depression, 14–16
 - electroconvulsive therapy (ECT), 114
 - and MAO-A activity, 95
 - monoamine hypothesis of, 26, 53–54
 - monoamine receptor hypothesis and gene expression, 26–33
 - neurotransmitter receptor hypothesis, 54–56
 - in perimenopausal women, 71–72
 - physiological effects, 77–81
 - symptoms and circuits, 37–42
 - transcranial magnetic stimulation (TMS), 114–115
 - treatment strategy, 48–49
 - vulnerability genes, 33–37
- See also* mood disorders
- depression treatment
- postpartum depression, 125
 - pregnant patient, 121–125
- depression with hypomania, 12–14
- depressive temperament, 2
- Deprimyl, 106
- desipramine, 76, 106–107
- desvenlafaxine,
- properties, 71–72
- dextromethorphan, 99, 103
- action on NMDA receptors, 130
- dichotomous disease model, 7–9
- dihydrofolate, 110
- disease progression in major depression, 53
- dopa decarboxylase, 21
- dopamine, 1
- norepinephrine precursor, 21
- dopamine beta hydroxylase, 21
- dothiapiin, 106
- doxepin, 106
- drugs of abuse, 103
- duloxetine,
- properties, 72–73
- dysthymia, 2
- eating disorders, 54
- edivoxetine
- norepinephrine reuptake inhibitor (NERI), 77
- Elavil, 106
- electroconvulsive therapy (ECT)
- use in depression, 114
- Endep, 106
- epigenetics,
- effects of psychotherapy, 116–117
- epistasis, 112–114
- ERK/AKT signal transduction
- cascade, 130
- escitalopram
- unique properties, 64
- estrogen replacement therapy (ERT), 71, 125
- eszopiclone, 105
- euthymia, 2
- fibromyalgia,
- milnacipran treatment, 73
- fluoxetine, 77, 104
- 5HT_{2C} antagonist properties, 61
 - unique properties, 61
- fluvoxamine,
- sigma 1 receptor binding, 63
 - unique properties, 63
- folate, 110, 112
- Gamanil, 106
- genetic testing
- aid to antidepressant selection, 125–126
- glucocorticoid antagonists, 129
- glucocorticoid levels
- effects of stress, 32–33
- GSK372475 (triple reuptake inhibitor), 129
- hippocampus
- effects of stress, 32–33
- histamine H1 receptor antagonists, 82
- homocysteine, 112
- HPA (hypothalamic-pituitary-adrenal) axis, 129

Index

- HPA (hypothalamic-pituitary-adrenal) axis (cont.)
 abnormalities in depression, 77
 effects of stress, 32–33
- Hunter Serotonin Toxicity Criteria, 99
- hydrocodone, 104
- hyperthymic temperament, 2
 and mood disorders, 12–16
- hypomania, 2
 with depression, 12–14
- imipramine, 106
- interpersonal therapy, 117
- iproniazid, 90
- isocarboxazid, 91
- ketamine, 114
 antidepressant effects, 129–130
- Kraepelin, Emil, 7
- lamotrigine, 105
- levodopa, 91
- lithium, 103, 110
- lofepramine, 106
- Loroxyl, 106
- LuAA24530 (triple reuptake inhibitor), 129
- Ludiomil, 106
- major depressive disorder, 2, 12
 disease progression concept, 53
 in perimenopausal women, 71–72
 use of combination antidepressant therapies, 126–129
- mania, 1–2, 9
 symptoms and circuits, 42–43 *See also* mood disorders
- maprotiline, 76, 106–107
- meclobemide, 97
- melancholic depression, 9
- melatonin secretion
 and depression, 77–81
- meperidine, 103–104
- methadone, 104
- methionine synthase, 112
- methionine synthase reductase, 112
- methylenetetrahydrofolate reductase
 genetic variants, 112–114
- L-methylfolate, 110–114
- methylphenidate, 62
- mianserin, 82–86
- milnacipran
 properties, 73
- mirtazapine, 77, 82–86
 California rocket fuel (SNRI plus mirtazapine), 82, 127
- mitochondria, 21
- mivacurium, 99
- mixed state mood disorders, 2, 9
- monoamine hypothesis of depression, 26, 53–54
- monoamine neurotransmitters
 and mood disorders, 1
- monoamine oxidase A (MAO-A), 21, 91–95
 and depression, 95
 reversible inhibitors of MAO-A (RIMAs), 97–99
- monoamine oxidase B (MAO-B), 21, 91–95
- monoamine oxidase inhibitors (MAOIs), 90–106
 avoidance of serotonergic agents, 99–103
 clinical management solutions, 95–106
 dietary tyramine interaction, 95–99
 drug–drug interactions, 99–104
 interactions with analgesics, 104
 interactions with anesthetics, 99
 interactions with decongestants, 99
 interactions with opiates, 104
 interactions with tricyclic antidepressants, 103–104
 MAO-A activity and depression, 95
 MAO subtypes, 91–95
 myths and misinformation, 95–104
 reversible inhibitors of MAO-A (RIMAs), 97–99
 risk of hypertensive crisis, 95–99
 risk of serotonin toxicity/serotonin syndrome, 99–103
 switching to and from, 104–106
 sympathomimetics to avoid or administer with caution, 99
- monoamine receptor hypothesis of depression
 and gene expression, 26–33
- monoamine transporter blockers, 53–110
- monoamines
 interactions between, 26
- mood disorders, 1
 bipolar depression, 1–2
 bipolar disorder NOS (not otherwise specified), 7–8
 bipolar spectrum, 7–14
 bipolar ¼ (0.25) disorder, 9
 bipolar ½ (0.5) disorder, 7–11
 bipolar I disorder, 2
 bipolar I ½ (1.5) disorder, 12
 bipolar II disorder, 2
 bipolar II ½ (2.5) disorder, 11
 bipolar III (3.0) disorder, 11–14
 bipolar III ½ (3.5) disorder, 15
 bipolar IV (4.0) disorder, 12–16
 bipolar V (5.0) disorder, 12–14
 bipolar VI (6.0) disorder, 14
- bipolarity comorbid with dementia, 14
 caused by antidepressants, 11–14
 continuum disease model, 9–11
 cyclothymic disorder, 2, 11
 depression, 1–2
 depression symptoms and circuits, 37–42
 depression with hypomania, 12–14
 depressive temperament, 2
 description, 1–2
 dichotomous disease model, 7–9
 distinguishing unipolar from bipolar depression, 14–16
 double depression, 2
 dysthymia, 2
 future treatments, 129–130
 hyperthymic temperament, 2, 12–16
 hypomania, 2
 major depressive disorder, 2, 12
 mania, 1–2
 mania symptoms and circuits, 42–43
 mixed mood state, 2
 monoamine hypothesis of depression, 26
 and monoamine neurotransmitters, 1
 monoamine receptor hypothesis and gene expression, 26–33
 mood-centered perspective, 8
 mood chart, 2
 mood-related temperaments, 2
 natural history, 16–17
 neuroimaging, 44–45
 neurotransmitter systems involved, 19
 question of progression, 16–17
 range of moods, 2
 rapid cycling, 2
 related to substance abuse, 15
 relationship to psychotic disorders, 7–11
 schizoaffective disorder, 7–11
 schizo-bipolar disorder, 7–11
 stress and depression, 32–37
 unipolar depression, 1–2
- morphine, 99
- mTOR (mammalian target of rapamycin) pathway, 130
- nefazodone, 86
- neurodegenerative disorders, 91–93
- neuroimaging
 mood disorders, 44–45
- neurotransmitter receptor hypothesis of depression, 54–56
- nicotine addiction, 75
- NMDA blockade

- potential treatment for mood disorders, 129–130
- nonsteroidal anti-inflammatory drugs, 104
- noradrenergic neurons, 19–26
- norepinephrine, 1
regulation of 5HT release, 26
- norepinephrine dopamine reuptake inhibitors (NDRIs), 73–76
in triple action combination (SSRI/SNRI/NDRI), 126–127
- norepinephrine receptors, 22–26
- norepinephrine reuptake inhibitors (NERIs)
edivoxetine, 77
See also selective norepinephrine reuptake inhibitors (NRIs)
- norepinephrine transporter (NET), 21–22
See also SNRIs, 70
- norepinephrine transporter (NET) inhibition
selective NRIs, 76–77
- norfluoxetine, 105
- Norpramin, 106
- nortriptyline, 106–107
- obsessive–compulsive disorder (OCD), 63, 110
- olanzapine, 77
- opiates
interactions with MAOIs, 104
- opioids
interaction with MAOIs, 103
- oxcarbazepine, 104
- pain
low back pain treatment, 110
psychic pain, 72–73
somatic pain, 72–73
- pain treatments,
duloxetine, 72–73
- Pamelor, 106
- panic attacks, 110
- panic disorder, 91
- paranoid personality disorder, 9
- Parkinson's disease, 115
use of MAO-B inhibitors, 91–93
- paroxetine
discontinuation reactions, 62–63
side effects, 62–63
unique properties, 62–63
- perimenopausal women
effectiveness of SSRIs and SNRIs, 71–72
treatment of depression, 71–72
vasomotor symptoms, 69, 71–72
- Pertofran, 106
- pharmaceutical industry, 50
- phenelzine, 91
- placebo effect
in antidepressant clinical trials, 49
- postmenopausal women
effectiveness of SSRIs and SNRIs, 72
- postpartum depression, 9, 125
- postpartum psychosis, 125
- posttraumatic stress disorder (PTSD), 32
- PRC200-SS (triple reuptake inhibitor), 129
- pregnancy
treatment of depression, 121–125
- premenstrual dysphoric disorder, 54
- Prothiaden, 106
- protriptyline, 106–107
- pseudobulbar affect, 130
- psychotherapy
combined with antidepressants, 116–117
as an epigenetic “drug”, 116–117
- psychotic depression, 9
- psychotic disorders
relationship to mood disorders, 7–11
- quetiapine, 64, 77
- quinidine, 130
- racemic citalopram, 63
- radafaxine, 74
- rapacuronium, 99
- rapid cycling in mood disorders, 2
- rasagiline, 91
- reboxetine, 76
- reversible inhibitors of MAO-A (RIMAs), 97–99
- SAMe (S-adenosyl-methionine), 114
- schizoaffective disorder, 7–11
- schizobipolar disorder, 7–11
- schizoid personality disorder, 9
- schizophrenia,
relationship to mood disorders, 7–11
- schizophreniform disorder, 9
- schizotypal personality disorder, 9
- scopolamine, 114
- seasonal affective disorder, 9
- selective norepinephrine reuptake inhibitors (NRIs)
atomoxetine, 76
reboxetine, 76
- selegiline, 91, 97
- SEP-225289 (triple reuptake inhibitor), 129
- serotonin, 1
- serotonin antagonist/reuptake inhibitors (SARIs), 86–90
- serotonin norepinephrine dopamine reuptake inhibitors (SNDRI), 129
- serotonin norepinephrine reuptake inhibitors (SNRIs), 66–73
California rocket fuel (SNRI plus mirtazapine), 127
desvenlafaxine, 71–72
dopamine increase in the prefrontal cortex, 69–70
duloxetine, 72–73
effectiveness in postmenopausal women, 72
effects of NET inhibition, 69–70
milnacipran, 73
in triple action combination (SSRI/SNRI/NDRI), 126–127
venlafaxine, 70–71
- serotonin partial agonist reuptake inhibitors (SPARIs)
vilazodone, 64–66
- serotonin selective reuptake inhibitors (SSRIs), 54–64
citalopram, 63
common features, 55–60
discontinuation reactions, 62–63
effectiveness in postmenopausal women, 72
escitalopram, 64
fluoxetine, 61
fluvoxamine, 63
paroxetine, 62–63
SERT blockade, 55–60
sertraline, 61–62
in triple action combination (SSRI/SNRI/NDRI), 126–127
unique properties of individual SSRIs, 60–64
- serotonin toxicity/serotonin syndrome
risk with MAOIs, 99–103
- serotonin transporter (SERT),
blockade by SSRIs, 55–60
- sertraline
dopamine receptor (DAT) inhibition, 61–62
sigma 1 receptor binding, 61–62
unique properties, 61–62
- setiptilene, 82
- shared psychotic disorder, 9
- sigma 1 receptor binding
fluvoxamine, 63
sertraline, 61–62
- Sinequan, 106
- sleep deprivation, 114
- social phobia, 91
- Stablon, 106
- STAR-D trial of antidepressants, 51
- Sternbach criteria for serotonin toxicity, 99

Index

- stress, 129
 BDNF effects, 32–33
 brain atrophy and depression, 32–33
 and depression vulnerability genes, 33–37
 effects of environmental stress, 37
 effects on glucocorticoid levels, 32–33
 effects on the hippocampus, 32–33
 effects on the HPA (hypothalamic-pituitary-adrenal) axis, 32–33
 and vulnerability to depression, 37
 substance abuse
 mood disorders related to, 15
 subsyndromal/ultra-high-risk
 psychosis prodrome, 9
 suprachiasmatic nucleus (SCN), 77–81
 Surmontil, 106
- tapentadol, 104
 tasofensine, 129
 temperaments
 mood-related, 2
 tetrahydrobiopterin (BH4), 110
- thyroid hormones,
 as antidepressant augmenting
 agents, 114
 tianeptine, 106
 Tofranil, 106
 tramadol, 103–104
 transcranial magnetic stimulation
 (TMS), 114–115
 tranlycypromine, 91
 trazodone, 86–90, 105
 trial-based therapy, 117
 tricyclic antidepressants, 76, 106–110
 interactions with MAOIs, 103–104
 potential for death in overdose,
 107–110
 side effects, 107–110
 trimipramine, 106
 triple reuptake inhibitors (TRIs), 129
 TriRima (CX157), 99
 Tryprizol, 106
 tryptophan hydroxylase, 110
 tyramine in the diet
 interaction with MAOIs, 95–99
 tyrosine, 21
 tyrosine hydroxylase, 21, 110
- unipolar depression, 1–2
 distinguishing from bipolar
 depression, 14–16
- valproate, 105
 vasomotor symptoms
 in perimenopausal women, 71–72
 vasopressin 1B antagonists, 129
 venlafaxine, 68
 extended-release formulation, 71
 properties, 70–71
 venlafaxine XR, 71
 vesicular monoamine transporter 2
 (VMAT2), 22
 vilazodone, 64–66, 129
 Vivactil, 106
 vortioxetine, 129
- Wellbutrin, 62
- Z-drugs, 105
 zaleplon, 105
 ziprasidone, 106
 Zolof, 62
 zolpidem, 105